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Abstract—In the frame of the Flemish Community funded 
project Bioflex we developed and fabricated an implant for 
short term bladder pressure monitoring, and diagnosis of 
incontinence. This implant is soft and flexible to prevent 
damaging the bladder’s inner wall, and designed for a 7 days 
long implantation. It is based on a standard flexible electronic 
circuit connected to a battery, embedded in silicone, of which 
the surface is treated to enhance the biocompatibility and to 
prevent salt deposition. This article describes the fabrication of 
the pill. The implantation and the result of the in-vivo 
experimentation will be presented in another article.  
I. INTRODUCTION 
n the frame of the Flemish Community funded project 
called Bioflex [4], research has been focused on the 
development of biocompatible, flexible or stretchable, 
electronic systems for implantation, based on PDMS 
substrates. This project is based on a consortium of 
universities and research groups. The MICAS group of the 
Katholieke Universiteit Leuven is responsible for designing 
electronic systems for biomedical applications. The CMST 
group of the University of Ghent is responsible for the 
technology development. The PBM group of the University 
of Ghent is responsible for the material development, and 
especially of the PDMS surface modification. The Histology 
group of the University of Ghent is responsible for the in 
vitro cytotoxicity tests and in vivo experimentations.  The 
Bioflex consortium is also working with the faculty of 
veterinary medicine of Ghent for in-vivo implantation. 
This article describes the development of a low cost flexible 
implantable pill for short term (7 days) pressure monitoring 
inside the bladder. Development of stretchable electronic has 
been described in several articles [3, 5]. Moreover, this 
article is a short presentation of the implantable pill.  Each 
part of the process, and detailed results and description will 
be published afterwards. 
The development of the implantable pill is done in four 
phases: electronic system development and tests of 
functionality, fabrication and encapsulation in PDMS of the 
implant, surface modification of the pill, and toxicology test. 
II. METHODOLOGY 
In order to monitor during a short term (7days) the pressure 
inside the bladder for diagnostic purposes of urinal or  
 
 
 
nephrological disorders [6], the idea is to install a pill shaped 
implant inside, to record the pressure during one week, and 
then to recuperate the pill using natural way, for data 
analysis by the doctor[1].  We want to develop a low cost 
implant, using standard and available technologies, 
biocompatible enough to be inside a bladder during 7 days, 
and as soft as possible. As the bladder is a very stretchable 
organ, the implant should be soft and conformable enough 
not to harm the bladder inner wall when its volume is 
minimal, and to float when the bladder is filling with urine. 
The implant is pill shaped in order to enable the introduction 
in the bladder with a catheter. This constraint forces us to 
have very thigh geometrical constraints, in order to fit as 
many functions as possible within a maximum diameter of 
5mm. The length of the pill is not as critical, however the 
smaller the better. As a trade-off between implement ability 
and need-for-space, a length of 40 mm has been defined. 
Different shapes of the implant have been tested (pill shape, 
pill with flaps to extend the surface of the pill, pill with 
whiskers to avoid undesirable evacuation), however the 
functional implant is a pill shape, as it is the easiest to 
implant using a catheter.  
Two solutions for electronic systems were possible. In the 
first solution, the pill has no battery, and it is powered using 
an inductive link. This inductive link is also used for 
communication [2]. However the position and the orientation 
of the implant in the bladder are always changing. So in 
order to have a correct coupling between the implant and the 
outside a 3D inductive coupling should be set from the 
inside to the outside of the bladder, which is not a 
convenient solution for the patient, and is also volume 
consuming for the implant. The second solution is to 
integrate a battery and a memory into the implant.  Therefore 
communication is not possible during the implantation; it is 
not possible to control the functionality or the data during 
experimentation. Moreover a battery is highly volume 
consuming, capacity is limited, and no flexible battery with 
enough capacity exists yet. A mixed solution which consists 
in a battery and a communication system is even more 
volume consuming, even though it would be a better 
solution in term of functionality. 
The sensor is a key part of the device. The sensor should be 
protected from the fluids; however it should be able to sense 
the pressure. So the protection should be as minimal as 
possible. Therefore a window is created in the encapsulation, 
in order to cover the sensor with just a very thin PDMS 
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membrane of 100 µm. Moreover, as urine is a very salty 
solution, salt deposition can happen on the surface of the 
PDMS, which can affect the mechanical properties of the 
membrane, affecting the measurements. A surface treatment, 
to enhance the biocompatibility of the PDMS and to prevent 
the deposition of salt on its surface is therefore needed. 
III. RESULT 
A. Electronic Design 
 
The electronic design of this application was done taking 
into account the following rules: everything must fit into a 
5mm diameter capsule with a length of 40mm including the 
battery; data must be stored on a memory module and read 
out after extraction of the implant and the power from the 
battery must be able to be switched off after encapsulation. 
The block diagram of the bladder pill is depicted in Figure 1. 
The device uses a surface machined capacitive absolute 
pressure sensor from MicroFab (E1.3N). Its range (0.5 to 
1.3bar) and size are perfectly suited for the application. This 
signal is digitized by a capacitance to digital converter from 
Analog Devices (AD7153). The CDC is a dedicated IC 
configured and controlled through I2C. To conserve as much 
power as possible, it is set to single conversion mode in a 
range of 0.25pF. 
The backbone is a microcontroller unit (MCU) adding 
intelligence to the device. The choice in MCU involves an 
important tradeoff: the physical size must me as small as 
possible, yet this comes with limited functionalities and 
programming memory. The PIC10F206 from Microchip was 
selected mainly for its tiny SOT23 package. Its sole useful 
(for this application that is) functionalities are: an on board 
clock oscillator and an 8 bit timer. All other needed 
functionalities: time tracking, configuration of the CDC at 
startup, I2C communication and the processing and storing 
of the results, are implemented in its 512k program memory. 
The MCU will fetch a CDC result every 500ms. Data will 
eventually be stored in an EEPROM memory of 16Kbyte, 
which was selected for it also uses I2C, and its miniature size 
in a 5pin SOT23 package. It is because of this limited 
memory the MCU must first process the results.  
A data result of 16 bits will contain only 5 bits of pressure 
data and 11 bits of timing data. Focus was shifted from 
pressure accuracy to time because in this first stage, pressure 
measurements do not need to be accurate making sure that a 
lot of data can be stored. Since the expected bladder pressure 
remains the same for long periods, this would make sure that 
in an ideal case where 211 consecutive pressure samples, 
covering 1024s of the same pressure reading, will only take 
up 16 bits of data. 
Power to all components comes indirectly from a 3mm 
diameter pin-type lithium battery with a body of 13mm. Its 
capacity is a mere 13mAh. To conserve power between 
production and implantation, a magnetic switch circuit is 
introduced with a reed switch and a D-Flip-Flop. A 0603-
size LED is also used to signal the on and off state of the 
device.  
Both measuring and power switch circuitries were then fitted 
onto a double-sided flex sizing 4.2x18mm2. From this file, 
the component outlines were put into an AutoCAD file to 
help the production of the molds for the actual fabrication, 
which will be discussed later. This AutoCAD design is 
shown in Figure 2. It also gives a general idea on how the 
pill will look like and what the relative sizes of the different 
components are. 
 
 
Figure 1 Block diagram of the bladder pill 
 
Figure 2 3D-Model of the bladder pill showing the 
battery and circuitry in a pill measuring ø 5mm x 40mm 
B. Programming 
The microcontroller is programmed before soldering on the 
electronic flexible substrate. When the implant is switched 
on, a LED is blinking and the microcontroller takes pressure 
measurements during 8 seconds, and then switches to sleep 
mode during 5 hours. Then it starts taking a pressure 
measurement once every 0.5 seconds until the memory is 
full or until the battery is empty. The data are then recovered 
after extraction of the pill by reading directly the EEPROM. 
C. Fabrication of the implant 
From the electronic design layout, the photolithographic 
masks are edited for the fabrication of the flex. At first, a 
polyimide substrate coated on both sides with copper 
(UPILEX, 25 µm of polyimide, 9 µm of copper on both 
sides) is laser drilled to define the vias and the alignment 
marks). Then, a superficial layer of copper is electroless 
plated to make the vias conductive. Then, copper is 
electroplated to obtain a total additional copper layer of 10 
µm on both sides and in the vias. The following step is to 
process lithography on both sides, and copper is etched in 
CuCl2 based etchant. After stripping in NaOH, solder mask 
ELPEMER SD 2463 Flex HD is screen printed and cured. 
Then electroless plating of Ni/Au finish the surface of the 
mask. 
  
The second step in the fabrication is the soldering of the 
components. A lead free solder paste (Delphine, 
SnAg(3%)Cu(0.5%) ) is dispensed on the pads, components 
are placed and soldering is done in a reflow oven at 270 ºC. 
After soldering the two sides, the flex is cut off the substrate 
using a YAG laser. Figure 3 shows the flexible substrate at 
the three stages: after lithography, after Ni/Au finishing and 
after components soldering. After functionality testing, the 
flexes are ready to be encapsulated. 
 
 
 
Figure 3 Fabrication of the flexible electronic substrate 
 
From the 3D model (Figure 2), the injection mould for the 
external shape of the implant and of the Teflon holder to 
fixate the system during molding are designed in AutoCAD. 
The mould is fabricated from transparent PMMA, 
transparent enough to control the injection and to avoid any 
air bubble formation. The tool used to fabricate the mould is 
a digital milling machine. The measurement of the 
smoothness of mould is done with WYKO laser 
profilometer, the roughness of the mould is 13 µm. In order 
to fixate the flexible substrate and the battery during the 
molding, a Teflon holder is processed in the same way. The 
precision of the Teflon holder is crucial to obtain a correct 
positioning of the sensor in the pill. A precision of 50 µm is 
obtained. Then tests to check the mould are performed, in 
order to control the thickness of the membrane on the top of 
the sensor. The thickness varies from 76 µm to 170 µm. As 
there is no sufficiently small battery connector, we are using 
a copper filament with a 40 µm diameter wrapped tidily 
around the battery and soldered with lead free solder. The 
battery is then soldered to the flex using these wires. The 
implant is put into switched-off state and then dipped in 
ethanol to clean, dried at room temperature during 1 hour, 
and then it is dipped in biocompatible adhesion promoter 
(NUSIL MED6-161). After 45 minutes, the adhesion 
promoter is hydrolyzed enough. Then the system (flex and 
battery) is glued on the holder with MDX 4210 
Biocompatible silicone rubber from Dow Corning. The glue 
is cured at 40 °C during 4 hours to avoid any thermal 
deformation of the mould and to avoid overheating the 
battery.  The top of the system is coated again with the 
adhesion promoter using the same process, and then the top 
mould is set on the holder and screwed tidily. Fully degassed 
MDX 4210 biocompatible PDMS is then injected using a 
syringe and a vacuum pomp to remove any entrapped air 
during the injection to avoid air bubbles. Then the PDMS is 
cured at room temperature during 24 hours. Afterwards, the 
holder is removed, and as the adhesion Silicone/PMMA is 
higher than the adhesion Silicone/Teflon, the molded system 
stays in the top mould. To enhance wet ability of the 
silicone, the molded system is plasma treated (low pressure 
air plasma, 0.8 mbar air, 197W, 30s). To enhance the 
adhesion silicone/silicone, the surface is coated with the 
biocompatible adhesion promoter using the same process. 
After sealing the bottom mould to the top mould, MDX 4210 
is injected in the bottom mould. After 24hours of curing at 
room temperature, the pill is un-molded, the overflowed 
PDMS cut out with a sharp scalpel and the pill is cleaned in 
ethanol and its functionality is tested. 
 
Figure 4 Implant after encapsulation in MDX 4210 
PDMS 
D. PDMS surface modification 
In order to reduce the deposition of salts (encrustration 
problem) on the surface of the bladder implant, the device 
was surface modified by plasma induced grafting of 
acrylamidopropyl sulfonic acid (AMPS) or sulfobetaïne. The 
grafted surfaces were analysed by contact angle 
measurements, XPS and FT-IR surface imaging. In vitro and 
preliminary in vivo experiments have demonstrated that such 
surface modification significantly reduces the salt 
deposition.  
E. Toxicity test 
In order to control the biocompatibility of the implant 
(material+process), a cytotoxicity test of 8 days is 
performed. Cytotoxicity tests with the extraction products of 
the silicone materials in culture medium were performed in 
triplicate in order to evaluate the presence of toxic 
leachables and metals, following the ISO 10 993-1 
guidelines. Samples were sterilized by ethylene oxide gas. 
The extraction took place in a tube with 2.5 ml culture 
medium (Hank’s medium with 10 vol% Fetal bovine serum) 
at 37°C under dynamic conditions for 1 week. This medium 
was subsequently added to a subconfluent cell layer of 
primary derived chicken embryo fibroblasts. 24 hours later, 
the influence of the extraction products on the cell viability 
was evaluated with the MTT assay. The mitochondria of 
viable cells reduced this MTT tetrazolium salt into a 
formazan product. After dissolving the formazan in 
isopropanol/HCl with 1% Triton X100, the absorbance could 
  
be determined spectrophotometrically (λ=580 nm). This 
absorbance value is proportional to the number of viable 
cells and can be compared to the absorbance value of control 
cell culture without contact with the extraction medium.  
The protocol is: extraction in long cryoval (2.5ml per pill), 
dynamic incubation at 37 ºC during 1 week in Hanks+FCS 
incubation medium. Then extraction medium is used 
immediately to react with 7 days old chicken embryo 
fibroblasts in a well. Each well contains 40 000 cells and the 
extraction test reactant. The extraction test reactant is MTT. 
MTT is based on tetrazolium salt which is reduced to 
formazan by the fibroblasts if they are alive. MTT turns 
from translucent to purple if the cells are alive. After 4 hours 
of incubation, a light absorbance test is performed to 
determine the percentage of cell survival. The absorbance of 
the formazan product is directly proportional to the number 
of viable cells in the culture. 
The rate of viability is the ratio of the absorbance of the 
sample with the absorbance of a control sample. 6 samples 
of the pill implant were tested: 2 samples of a battery 
embedded in the silicone pill (Battery A and Battery B),  2 
samples of a battery and flex embedded in the silicone pill 
(Flex A and Flex B) and 2 samples of a battery + flex + 
components embedded in the silicone pill (Components A 
and Components B) (Figure 5). 
 
Figure 5 In Vitro biocompatibility tests of the implant 
 
The vialibity of the implant for 7 days ranges from 78% to 
98%. Therefore it shows that the implant is not toxic for an 
implantation of 7 days in the bladder. Deeper analyses will 
be developped in forthcomings articles. 
IV. DISCUSSION 
We have been able to produce a biocompatible, soft and 
flexible implant to measure the pressure in the bladder, using 
standard PCB technologies and PDMS encapsulation. 
Functionality has been tested as well. However, in-vivo 
experimentations and biological aspects of the implant have 
not been presented yet.  
The production of this implant is low cost, as it uses only 
standard PCB technologies and commonly available 
components. The biocompatibility is limited to 7 days, as it 
is a diagnostic implant, and to reach this biocompatibility, 
the PDMS rubber MDX 4210 from Dow Corning is 
sufficient. However, post implantation biological analysis is 
needed to prove the biocompatibility of this implant. 
Biological analysis will have to prove the biochemical and 
biological compatibility, as well as the mechanical 
compatibility: As the bladder is a very elastic organ, the 
implant should not harm the inner wall. 
V. CONCLUSION 
This implant is a demonstration that low cost biocompatible 
implants can be produced for short term implantation for 
diagnostic purposes. Several improvements are needed: 
reducing the volume to ease the implantation using natural 
ways, improving the power management to increase the 
storage time and reduce the battery size, using bare chips 
instead of packaged chips to reduce the volume of the 
implant.  However designing an implant for short term 
diagnostic purpose is a tradeoff between volume, cost and 
functionality.  
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